

**Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against *Acinetobacter baumannii***

Mohd Hafidz Mahamad Maifiah<sup>1</sup>, Darren J. Creek<sup>1,†</sup>, Roger L. Nation<sup>1</sup>, Alan Forrest<sup>2</sup>, Brian T. Tsuji<sup>3</sup>, Tony Velkov<sup>1</sup>, Jian Li<sup>4,†,\*</sup>

<sup>1</sup>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.

<sup>2</sup>UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7569, USA.

<sup>3</sup>Department of Pharmacy Practice, University at Buffalo, Buffalo, NY, USA.

<sup>4</sup>Biomedicine Discovery Institute, Department of Microbiology, Monash University VIC 3800, Australia.

†Joint senior authors: Jian Li, email: [Colistin.Polymyxin@gmail.com](mailto:Colistin.Polymyxin@gmail.com), phone: +61 3 9903 9702, fax: +61 3 9902 9222; Darren J. Creek, email: [darren.creek@monash.edu](mailto:darren.creek@monash.edu), phone: +61 3 9903 9249, fax: +61 3 9903 9583.


\*Corresponding author: Jian Li, email: [Colistin.Polymyxin@gmail.com](mailto:Colistin.Polymyxin@gmail.com)

## Supplementary Information


(A)

|               | Median RSD (%) |
|---------------|----------------|
| <b>15 min</b> |                |
| Control       | 18             |
| Colistin      | 28             |
| Doripenem     | 19             |
| Combo         | 30             |
| <b>1 hr</b>   |                |
| Control       | 18             |
| Colistin      | 23             |
| Doripenem     | 22             |
| Combo         | 19             |
| <b>4 hr</b>   |                |
| Control       | 26             |
| Colistin      | 24             |
| Doripenem     | 29             |
| Combo         | 21             |
| PBQCs         | 14             |










(B)



**Supplementary Figure S1. (A) Data precision of individual samples represented as the median relative standard deviation (RSD) for all metabolites based on all replicates (n=4) of each group (n=11 for technical replicates of PBQCs). (B) PCA score plot of all metabolites of *A. baumannii* ATCC 19606 treated with colistin and doripenem alone and in combination.** Eleven PBQCs were analyzed throughout the LC-MS batch. Each dataset represents four biological replicates of antibiotic-treated and untreated control samples of all the time points. Pooled biological quality controls = PBQCs.



**Supplementary Figure S2. Monotherapy and combination of colistin and doripenem induce global metabolic changes.** Heatmap profiles with hierarchical clustering of top 600 significantly changed metabolites after treatment with single and combination of colistin and doripenem at (A) 15 min, (B) 1 hr, and (C) 4 hr. Light blue = untreated control (Ctrl); Red = Colistin (Col); Blue = Doripenem (Dor); Green = colistin and doripenem combination (Col-Dor).  $p \leq 0.05$ , FDR  $\leq 0.1$ .

**(i)****(ii)****(iii)**

**Supplementary Figure S3. Summary number of metabolites changes classified according to different metabolite classes after antibiotic treatment at (i) 15 min, (ii) 1 hr, and (iii) 4 hr. Changes  $\geq 1.5\text{-log}_2\text{-fold}$ ,  $p \leq 0.05$ ,  $\text{FDR} \leq 0.1$  (one-way ANOVA for multiple comparison).**